# AstraZeneca’s Imfinzi approved in Japan for SCLC

- Link: https://www.directorstalkinterviews.com/astrazenecas-imfinzi-approved-in-japan-for-sclc/412852991
- Published: 2020-08-21T07:18:57+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has been approved in Japan for the treatment of patients with extensive-stage small
cell lung cancer (ES-SCLC), in combination with etoposide plus a choice of platinum
chemotherapy (either carboplatin or cisplatin). SCLC is a highly aggressive, fast-
growing form of lung cancer that typically recurs and progresses rapidly, despite
initial response to chemotherapy.^(1,2)

The approval by the Japanese Ministry of Health, Labour and Welfare was based on
positive results from the Phase III CASPIAN trial, showing _Imfinzi_ plus chemotherapy
demonstrated a statistically significant and clinically meaningful improvement in
overall survival (OS) versus chemotherapy alone. These results were published in
The Lancet in 2019.^(3)

> **Makoto Nishio MD, PhD, Director, Thoracic Medical Oncology, The Cancer Institute
> Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan and an investigator
> in the Phase III CASPIAN trial, said: **“Patients with extensive-stage small cell
> lung cancer in Japan are in urgent need of new options that can provide long-term
> tumour control and sustained improvements in overall survival. This approval of
> _Imfinzi_ provides Japanese patients with a new, effective and well-tolerated 
> 1st-line treatment option for this disease, and for the first time physicians 
> have the opportunity to combine immunotherapy with cisplatin for these patients.”

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said:** “
> This approval of _Imfinzi_ provides an important new immunotherapy option in Japan
> for patients with extensive-stage small cell lung cancer. These patients have 
> an especially poor prognosis, with only two per cent surviving beyond five years.
> _Imfinzi_, in combination with chemotherapy, delivers a sustained survival benefit
> and prolonged treatment response with a convenient dosing regimen given every 
> four weeks during maintenance.”

The CASPIAN trial met the primary endpoint of OS for _Imfinzi_ plus chemotherapy
in June 2019, reducing the risk of death by 27% versus chemotherapy alone (based
on a hazard ratio [HR] of 0.73; 95% confidence interval [CI] 0.59-0.91; p=0.0047),
with median OS of 13.0 months versus 10.3 months for chemotherapy alone. Results
also showed an increased confirmed objective response rate for _Imfinzi_ plus chemotherapy(
68% versus 58% for chemotherapy alone) and that _Imfinzi_ added to chemotherapy 
delayed the time for disease symptoms to worsen.

An updated analysis recently showed sustained efficacy for _Imfinzi_ plus chemotherapy
after a median follow up of more than two years (OS HR: 0.75; 95% CI 0.62-0.91; 
nominal p=0.0032), with median OS of 12.9 months versus 10.5 months for chemotherapy
alone. The safety and tolerability for _Imfinzi_ plus chemotherapy were consistent
with the known safety profile of these medicines. No patients tested positive for
treatment-emergent anti-drug antibodies to _Imfinzi_.

The efficacy and safety results for Japanese patients in the CASPIAN trial were 
consistent with the overall trial population in a prespecified analysis. The CASPIAN
trial used a fixed dose of _Imfinzi_ (1,500mg), administered every three weeks for
four cycles while in combination with chemotherapy and then every four weeks until
disease progression. 

_Imfinzi,_ in combination with etoposide and either carboplatin or cisplatin, is
also approved in the US and several other countries around the world for the treatment
of ES-SCLC in the 1st-line setting and is currently under regulatory review in other
countries. It was recently recommended for marketing authorisation in the EU for
this indication.

As part of a broad development programme, _Imfinzi_ is also being tested following
concurrent chemoradiation therapy in patients with limited-stage SCLC in the Phase
III ADRIATIC trial. 

**Small cell lung cancer**

Lung cancer is the leading cause of cancer death among both men and women and accounts
for about one fifth of all cancer deaths.^(4) In Japan, nearly 119,000 people were
diagnosed with lung cancer in 2018 and there were nearly 82,000 deaths from the 
disease.^(5) Lung cancer is broadly split into non-small cell lung cancer (NSCLC)
and SCLC, with about 15% classified as SCLC.^(6) About two thirds of SCLC patients
are diagnosed with ES-SCLC, in which the cancer has spread widely through the lung
or to other parts of the body.^(7) Prognosis is particularly poor, as only 6% of
all SCLC patients will be alive five years after diagnosis.^(7)

**Imfinzi**

_Imfinzi_ is a human monoclonal antibody that binds to PD-L1 and blocks the interaction
of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and 
releasing the inhibition of immune responses.

_Imfinzi_ is approved in the curative-intent setting of unresectable, Stage III 
NSCLC after chemoradiation therapy in the US, Japan, China, across the EU and in
many other countries, based on results from    the Phase III PACIFIC trial. _Imfinzi_
is also approved for previously treated patients with advanced bladder cancer in
the US and a small number of other countries.

As part of a broad development programme, _Imfinzi_ is also being tested as a monotherapy
and in combinations including with tremelimumab, an anti-CTLA4 monoclonal antibody
and potential new medicine, as a treatment for patients with NSCLC, SCLC, bladder
cancer, head and neck cancer, liver cancer, biliary tract cancer, cervical cancer,
ovarian cancer, endometrial cancer and other solid tumours.

**CASPIAN**

CASPIAN was a randomised, open-label, multi-centre, global Phase III trial in the
1st-line treatment of 805 patients with ES-SCLC. The trial compared _Imfinzi_ in
combination with etoposide and either carboplatin or cisplatin chemotherapy, or 
_Imfinzi_ and chemotherapy with the addition of a second immunotherapy, tremelimumab,
versus chemotherapy alone. In the experimental arms, patients were treated with 
four cycles of chemotherapy. In comparison, the control arm allowed up to six cycles
of chemotherapy and optional prophylactic cranial irradiation. The trial was conducted
in more than 200 centres across 23 countries, including the US, in Europe, South
America, Asia and the Middle East. The primary endpoint was OS in each of the two
experimental arms. In June 2019, AstraZeneca announced the CASPIAN trial had met
one primary endpoint of demonstrating OS for _Imfinzi_ plus chemotherapy at a planned
interim analysis. In March 2020, it was announced that the second experimental arm
with tremelimumab did not meet its primary endpoint of OS.

Share on:
